PARP inhibitors, Olaparib (AZD2281), Veliparib (ABT-888), and Iniparib (BSI-201) have been shown to be promising anti-cancer agents for breast and ovarian cancer and being tested in clinical trials. The gene discussed is PARP1; the disease is cancer.